BioSpace News Archive

Today, the U.S. Food and Drug Administration warned against using test strips from a previous owner (pre-owned) or test strips not authorized for sale in the U.S. because they may potentially cause infection or lead to inaccurate test results, which can cause serious harm, including death.

par8o, a leader in physician referral management solutions, and AdventHealth, one of the nation’s largest faith-based health care systems, are announcing the launch of the par8o platform to create better care coordination and enhance the consumer experience through more effective referral management across the health system’s network of care

Beat the stress of tax season with a free massage. HydroMassage and Planet Fitness are partnering for the 11th annual Free Massage During Tax Week offer, available between Thursday April 11th and Saturday April 20th.

POXEL SA (Euronext: POXEL –FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), today announced favorable results from the Phase 1a two-part study that included three single doses of PXL065 and a single dose of Actos®* (pioglitazone).

The first in a series of 40th-anniversary videos by VITAS® Healthcare, the nation’s leading provider of end-of-life care, chronicles the personal experiences and memories of VITAS team members who cared for thousands of patients during the HIV/AIDS crisis of the 1980s–'90s.

Exact Sciences Corp. announced that the company plans to release its first-quarter 2019 financial results after the close of the U.S. financial markets on Apr. 30, 2019.

United Therapeutics Corporation announced that the BEAT clinical study of esuberaprost tablets in patients suffering from pulmonary arterial hypertension did not meet its primary endpoint of delayed time to first clinical worsening event.

Axonics Modulation Technologies, Inc. announced that Nancy L. Snyderman, M.D. and Jane E. Kiernan have been appointed to the Axonics board of directors, effective immediately.

Partnership to focus on Alzheimer’s disease, breast cancer, diabetes, obesity

Asepticys LLC, a leading innovator and developer of anti-infective pharmaceutical and consumer healthcare products, today announced the successful completion of multi-site human clinical trials for Asepticys’ novel contact lens care solution containing TriFlect™ technology, and the submission of its 510k application to the U.S. Food and Drug Administration.